Cinnarizine
(Synonyms: 桂利嗪) 目录号 : GC11695
A calcium channel inhibitor and histamine H4 receptor antagonist
Cas No.:298-57-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cinnarizine is a calcium channel blocker.
Blockers of calcium channel are drugs disrupting the calcium movement via calcium channels, which are usually used as antihypertensive therapies to decrease blood pressure in hypertension patients.
In vitro: Previous study found that cinnarizine could inhibit the phosphorylation of both arterial myosin P-light chain and arterial actomyosin superprecipitation. Moreover, the concomitant inhibition of arterial superprecipitation and phosphorylation by perhexiline and cinnarizine was found to be similar to that of W-7. Such inhibitary effect was then characterized by a rightward shift in the pCa superprecipitation, depressed maximum activity as well as attenuation by exogenous calmodulin [1].
In vivo: Previous animal study showed that augmented effects were obtained in MES seizure model when cinnarizine was combined with sodium valproate. Whereas, in PTZ-induced seizures, augmented effects were obtained when nifedipine was combined with sodium valproate [2].
Clinical trial: The anti-vertigo effect of cinnarizine was evaluated in a double blinded, controlled study on fourty patients with well characterized peripheral or central vestibular disorders. Electronystagmography results did not show obviously detectable differences between patients treated with cinnarizine and placebo, and only a temporary depressant effect on vestibular nystagmus was observed in five healthy volunteers when cinnarizine dose was increased to 150 mg. In addition, cinnarizine was found to be generally well tolerated [3].
References:
[1] Silver PJ,Dachiw J,Ambrose JM,Pinto PB. Effects of the calcium antagonists perhexiline and cinnarizine on vascular and cardiac contractile protein function. J Pharmacol Exp Ther.1985 Sep;234(3):629-35.
[2] Brahmane RI,Wanmali VV,Pathak SS,Salwe KJ. Role of cinnarizine and nifedipine on anticonvulsant effect of sodium valproate and carbamazepine in maximal electroshock and pentylenetetrazole model of seizures in mice. J Pharmacol Pharmacother.2010 Jul;1(2):78-81.
[3] Hausler R,Sabani E,Rohr M. Effect of cinnarizine on various types of vertigo. Clinical and electronystagmographic results of a double-blind study. Acta Otorhinolaryngol Belg.1989;43(2):177-85.
| Cas No. | 298-57-7 | SDF | |
| 别名 | 桂利嗪 | ||
| 化学名 | 1-benzhydryl-4-cinnamylpiperazine | ||
| Canonical SMILES | C1(/C=C/CN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)=CC=CC=C1 | ||
| 分子式 | C26H28N2 | 分子量 | 368.51 |
| 溶解度 | DMF: 14 mg/ml,DMF:PBS(pH7.2) (1:2): 0.3 mg/mol,DMSO: 2 mg/ml,Ethanol: 3 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7136 mL | 13.5682 mL | 27.1363 mL |
| 5 mM | 0.5427 mL | 2.7136 mL | 5.4273 mL |
| 10 mM | 0.2714 mL | 1.3568 mL | 2.7136 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。